Indacaterol

EUEMA:by INNUSDailyMed:Indacaterol AU:B3 R03AC18(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-only 5-[2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one 312753-06-3Y 6433117 7455 DB05039Y 5293751Y 8OR09251MQ D09318Y CHEBI:68575N ChEMBL1095777Y DTXSID90185198 Interactive image O=C4/C=C\c1c(c(O)ccc1[C@@H](O)CNC3Cc2cc(c(cc2C3)CC)CC)N4 InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1YKey:QZZUEBNBZAPZLX-QFIPXVFZSA-NY Indacaterolis an ultra-long-acting beta-adrenoceptor agonistdeveloped byNovartis. It needs to be taken only once a day,unlike the related drugsformoterolandsalmeterol. It is licensed only for the treatment ofchronic obstructive pulmonary disease(COPD) (long-term data in patients withasthmaare thus far lacking). It is delivered through adry powder inhaler.